Quinine Sulfate
FDA-approved product (capsule, oral), marketed as Qualaquin, Quinine Sulfate.
- Registered studies
- 50+
- Lab records
- 1
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Malaria
- Muscle cramp
- Plasmodium falciparum malaria
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Quinine and derivatives; Methanolquinolines
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BC01
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis13.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- M. tuberculosis: measured active in 0 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Quinine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions
NCT00727272 · start 2004-02
Registered record
- Registry ID
- NCT00727272
- Conditions
- Healthy
- Interventions
- Quinine Sulfate Capsules 324 mg; Quinine Sulphate Tablets 300 mg; Quinine Sulfate Capsules 324 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-02
- Completion
- 2004-03
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionQuinine Sulfate Capsules 324 mg; Quinine Sulphate Tablets 300 mg; Quinine Sulfate Capsules 324 mgPhasePhase 1Registry statusCompletedTreatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine
NCT00167739 · start 2003-04
Registered record
- Registry ID
- NCT00167739
- Conditions
- Malaria
- Interventions
- Quinine plus sulfadoxine-pyrimethamine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-04
- Completion
- 2004-02
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMalariaInterventionQuinine plus sulfadoxine-pyrimethaminePhasePhase 4Registry statusCompletedCotrifazid Safety and Efficacy Against Malaria
NCT00322907 · start 2000-04
Registered record
- Registry ID
- NCT00322907
- Conditions
- Clinical Malaria
- Interventions
- Cotrifazid vs mefloquine or quinine+SP
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2000-04
- Completion
- 2003-01
- Enrolment
- 330
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionClinical MalariaInterventionCotrifazid vs mefloquine or quinine+SPPhasePhase 2Registry statusTerminatedInfluence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine
NCT00000706
Registered record
- Registry ID
- NCT00000706
- Conditions
- HIV Infections
- Interventions
- Quinine sulfate; Probenecid; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 1988-12
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionQuinine sulfate; Probenecid; ZidovudinePhaseNot applicableRegistry statusCompletedOtotoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials
NCT00451139
Registered record
- Registry ID
- NCT00451139
- Conditions
- Malaria
- Interventions
- artemether/lumefantrine; quinine; atovaquone/proguanil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMalariaInterventionartemether/lumefantrine; quinine; atovaquone/proguanilPhasePhase 4Registry statusCompleted